These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 6108751)

  • 1. gamma-Acetylenic GABA in tardive dyskinesia.
    Casey DE; Gerlach J; Magelund G; Christensen TR
    Arch Gen Psychiatry; 1980 Dec; 37(12):1376-9. PubMed ID: 6108751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of gamma-vinyl GABA in tardive dyskinesia.
    Korsgaard S; Casey DE; Gerlach J
    Psychiatry Res; 1983 Apr; 8(4):261-9. PubMed ID: 6136054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gamma-Acetylenic GABA in tardive dyskinesia.
    Casey DE; Gerlach J; Magelund G; Christensen TR
    Adv Biochem Psychopharmacol; 1980; 24():577-80. PubMed ID: 6105803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GABA agonist treatment improves tardive dyskinesia.
    Tamminga CA; Thaker GK; Ferraro TN; Hare TA
    Lancet; 1983 Jul; 2(8341):97-8. PubMed ID: 6134975
    [No Abstract]   [Full Text] [Related]  

  • 5. GABA agonists in cebus monkeys with neuroleptic-induced persistent dyskinesias.
    Andersson U; Häggström JE
    Psychopharmacology (Berl); 1988; 94(3):298-301. PubMed ID: 2895937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of tetrahydroisoxazolopyridinol (THIP) in tardive dyskinesia: a new gamma-aminobutyric acid agonist.
    Korsgaard S; Casey DE; Gerlach J; Hetmar O; Kaldan B; Mikkelsen LB
    Arch Gen Psychiatry; 1982 Sep; 39(9):1017-21. PubMed ID: 6126170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluperlapine in tardive dyskinesia and parkinsonism.
    Korsgaard S; Noring U; Gerlach J
    Psychopharmacology (Berl); 1984; 84(1):76-9. PubMed ID: 6149595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain gamma-aminobutyric acid abnormality in tardive dyskinesia. Reduction in cerebrospinal fluid GABA levels and therapeutic response to GABA agonist treatment.
    Thaker GK; Tamminga CA; Alphs LD; Lafferman J; Ferraro TN; Hare TA
    Arch Gen Psychiatry; 1987 Jun; 44(6):522-9. PubMed ID: 3034188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulpiride in tardive dyskinesia.
    Casey DE; Gerlach J; Simmelsgaard H
    Psychopharmacology (Berl); 1979; 66(1):73-7. PubMed ID: 44375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic trial of gamma-vinyl GABA, an inhibitor of GABA transaminase, in tardive dyskinesias induced by neuroleptics].
    Lambert PA; Cantiniaux P; Chabannes JP; Tell GP; Schechter PJ; Koch-Weser J
    Encephale; 1982; 8(3):371-6. PubMed ID: 6137357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Gamma-vinyl GABA and tardive dyskinesia: a single-blind study versus placebo].
    Danion JM; Singer L; Tell G; Schechter P
    Ann Med Psychol (Paris); 1984 Jan; 142(1):101-10. PubMed ID: 6476669
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of gamma-acetylenic GABA, an enzyme-activated irreversible inhibitor of GABA-transaminase, on dopamine pathways of the extrapyramidal and limbic systems.
    Palfreyman MG; Huot S; Lippert B; Schechter PJ
    Eur J Pharmacol; 1978 Aug; 50(4):325-36. PubMed ID: 699960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Movement disorders in patients with coexistent neuroleptic-induced tremor and tardive dyskinesia: EMG and pharmacological study.
    Rondot P; Bathien N
    Adv Neurol; 1987; 45():361-6. PubMed ID: 2881446
    [No Abstract]   [Full Text] [Related]  

  • 14. Tiapride in the treatment of tardive dyskinesia: a clinical and biochemical study.
    Perényi A; Arató M; Bagdy G; Frecska E; Szücs R
    J Clin Psychiatry; 1985 Jun; 46(6):229-31. PubMed ID: 2860098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and biochemical effects of gamma-vinyl Gaba in tardive dyskinesia.
    Gaio JM; Pollak P; Hommel M; Perret J
    J Neurol Neurosurg Psychiatry; 1987 Dec; 50(12):1674-8. PubMed ID: 3437301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine, GABA, cholecystokinin and opioids in neuroleptic-induced tardive dyskinesia.
    Ebadi M; Hama Y
    Neurosci Biobehav Rev; 1988; 12(3-4):179-87. PubMed ID: 2906420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gamma-vinyl-GABA treatment of tardive dyskinesia and other movement disorders.
    Stahl SM; Thornton JE; Simpson ML; Berger PA; Napoliello MJ
    Biol Psychiatry; 1985 Aug; 20(8):888-93. PubMed ID: 3861199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An analysis of the cortical and striatal involvement in dyskinesia induced in rats by intracerebral injection of GABA-transaminase inhibitors and picrotoxin.
    Robin MM; Palfreyman MG; Zraika MM; Schechter PJ
    Eur J Pharmacol; 1980 Apr; 62(4):319-27. PubMed ID: 6445277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased CSF gamma-aminobutyric acid after treatment with gamma-vinyl GABA.
    Grove J; Tell G; Schechter PJ; Koch-Weser J; Warter JM; Marescaux C; Rumbach L
    Lancet; 1980 Sep; 2(8195 pt 1):647. PubMed ID: 6107437
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of Huntington disease with gamma-acetylenic GABA an irreversible inhibitor of GABA-transaminase: increased CSF GABA and homocarnosine without clinical amelioration.
    Tell G; Böhlen P; Schechter PJ; Koch-Weser J; Agid Y; Bonnet AM; Coquillat G; Chazot G; Fischer C
    Neurology; 1981 Feb; 31(2):207-11. PubMed ID: 6258106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.